The valuation of healthtech and medtech entities represents one of the most complex exercises in corporate finance, requiring analysts to bridge the gap between long-term scientific development, binary regulatory approvals, capital intensive commercialisation and rapid technological obsolescence. Within a discounted cash flow (DCF) model, the terminal value is the single most critical and sensitive component of a company's total implied valuation, typically constituting betwe